Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients with Advanced Solid Tumors
May 26, 2022 08:00 ET
|
Yingli Pharma US, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Yingli Pharma US, Inc, (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs for cancers and other...
Yingli Pharma and MD Anderson Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs
January 20, 2022 11:00 ET
|
Yingli Pharma US, Inc.
SAN FRANCISCO and HOUSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Yingli Pharma US, Inc. (the “Company” or “Yingli”), a biotechnology company developing innovative small molecules, and The University of...